Palisade Bio
PALI
4 hedge funds and large institutions have $15.1M invested in Palisade Bio in 2015 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
46% more call options, than puts
Call options by funds: $182K | Put options by funds: $125K
0% less ownership
Funds ownership: 0% → 0% (-0%)
20% less funds holding
Funds holding: 5 → 4 (-1)
20% less capital invested
Capital invested by funds: $19M → $15.1M (-$3.89M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.35M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$513K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$19K |
| 4 |
NG
Northstar Group
New York
|
-$15K |
| 5 |
GWS
Glassman Wealth Services
Vienna,
Virginia
|
-$3K |
PALI Hedge Fund Activity: Q4 2015 in Review
4 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2015, worth a combined $15.1M — down 20% from $19M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PALI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Millennium Management, exiting entirely with an estimated $1.35M sold.
- 4 institutional investors held Palisade Bio (PALI) as of Q4 2015, down from 5 in Q3 2015.
- Funds reported $15.1M of Palisade Bio stock for Q4 2015, down 20% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q4 2015 and 1 closed out, a net change of -1 holder.
- The largest Palisade Bio seller in Q4 2015 was Millennium Management, an estimated $1.35M sold.
Based on aggregated 13F filings for Q4 2015.